tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hattori Y et al. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus. 2014 Transplant. Proc. pmid:24656015
Tanabe K et al. Prospective analysis and successful treatment of thrombotic microangiopathy in renal allografts under tacrolimus immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750571
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
Claesson K et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. 1998 Transplant. Proc. pmid:9636524
Furian L et al. Everolimus associated with low-dose calcineurin inhibitors, an option in kidney transplant recipients of very old donors. 2014 Transplant. Proc. pmid:25498057
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Bruce DS et al. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9532150
Peddi VR et al. Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9532151
Venkataramanan R et al. Pharmacokinetics of FK 506: preclinical and clinical studies. 1990 Transplant. Proc. pmid:1689899
Tanabe M et al. The influence of donor and recipient strains in isolated small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7527986
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Manu M et al. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119912
Weiler N et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? 2013 Jul-Aug Transplant. Proc. pmid:23953543
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Tanaka M et al. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. 1996 Transplant. Proc. pmid:8623341
Ye Q et al. Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. 1996 Transplant. Proc. pmid:8623350
Pascual J et al. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. 2005 Transplant. Proc. pmid:16386525
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Faivre L et al. FK 506 dose in transplantation: from theory to practice. 2001 Transplant. Proc. pmid:11406256
Lang M et al. Impact of immunosuppression in liver transplantation across a positive crossmatch. 1998 Transplant. Proc. pmid:9636595
Hatori M et al. Clinicopathologic examination of no-episode biopsies in well-functioning renal allografts. 1998 Transplant. Proc. pmid:9474971
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Sawai T et al. A successful induction of tolerance by perioperative intrathymic injection in rat "high-responder" heart transplantation. 1999 Transplant. Proc. pmid:10578275
Oberholzer J et al. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. 2005 Transplant. Proc. pmid:15848603
Kim SJ et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. 2009 Transplant. Proc. pmid:19545705
Akbas SH et al. Plasma homocysteine levels in renal transplant patients on tacrolimus therapy. 2004 Jan-Feb Transplant. Proc. pmid:15013332
Zhao J et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. 2009 Transplant. Proc. pmid:19545722
Sánchez-Lázaro IJ et al. Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. 2010 Transplant. Proc. pmid:20970650
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Spagnoletti G et al. Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up. 2014 Transplant. Proc. pmid:25242756
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
Costa JS et al. Polyomavirus Nephropathy: Ten-Year Experience. 2017 Transplant. Proc. pmid:28457399
Bäckman L et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. 1994 Transplant. Proc. pmid:7518160
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Celli S et al. Mechanisms of protection from humoral rejection by a xenografted liver. 1995 Transplant. Proc. pmid:7533395
Land W Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation. 1999 Transplant. Proc. pmid:10616558
Hasegawa A et al. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan. 2005 Transplant. Proc. pmid:15919460
Hasegawa A et al. Improvement of quality of life in tacrolimus-based pediatric renal transplant recipients and their caregivers, including donors. 2005 Transplant. Proc. pmid:15919461
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Jain AK et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. 2002 Transplant. Proc. pmid:12176474
Carmellini M et al. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure. 2008 Jul-Aug Transplant. Proc. pmid:18675070
Viganò J et al. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. 2008 Jul-Aug Transplant. Proc. pmid:18675099
Cakir U et al. Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28340820
Metcalfe SM et al. In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. 1998 Transplant. Proc. pmid:9865315
Rodrigues N et al. Serum Magnesium and Related Factors in Long-Term Renal Transplant Recipients: An Observational Study. 2017 Transplant. Proc. pmid:28457398
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
Scantlebury VP et al. Pediatric kidney transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7509095
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Falkiewicz K et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. 2006 Jan-Feb Transplant. Proc. pmid:16504680
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Pascual J et al. A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. 2003 Transplant. Proc. pmid:12962785
Rashid I et al. Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients. 2002 Transplant. Proc. pmid:12176520
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Fukushima N et al. Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. 1998 Transplant. Proc. pmid:9838671
Schulz T et al. Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. 1999 Feb-Mar Transplant. Proc. pmid:10083251
Schwarz C et al. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis. 2015 Transplant. Proc. pmid:26518948
Burke GW et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. 1997 Feb-Mar Transplant. Proc. pmid:9123275
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Jordán de Luna C et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. 2011 Jul-Aug Transplant. Proc. pmid:21839244
Büttemeyer R et al. Peripheral nerve allotransplant immunosuppressed with FK 506: preliminary results. 1995 Transplant. Proc. pmid:7536979
Muirhead N et al. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years. 2003 Transplant. Proc. pmid:14611965
Bunnapradist S and Takemoto SK Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. 2003 Transplant. Proc. pmid:14611971
Tsao CI et al. Unplanned readmission within 1 year after heart transplantation in Taiwan. 2010 Transplant. Proc. pmid:20430212
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Fang YH et al. AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report. 2010 Transplant. Proc. pmid:20430219
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Boucher A et al. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. 2002 Transplant. Proc. pmid:12176582
Fellermann K et al. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. 2001 Transplant. Proc. pmid:11377517
Suwelack B et al. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. 2002 Transplant. Proc. pmid:12176585
Salizzoni M et al. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. 2001 Transplant. Proc. pmid:11377521
El Haggan W et al. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176589
Chang HR et al. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients. 2007 Transplant. Proc. pmid:18089339
Jiang H et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. 2001 Feb-Mar Transplant. Proc. pmid:11266931
Wilberg J et al. Oral tacrolimus bioavailability is increased after right split liver transplantation. 2007 Transplant. Proc. pmid:18089362
Orsenigo R et al. FK506 and SMS 201-995: effect on heterotopic heart transplantation in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266956
Cirocco RE et al. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. 1999 Feb-Mar Transplant. Proc. pmid:10083604
Ji SM et al. Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results. 2014 Transplant. Proc. pmid:25498056
Htun YY et al. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. 2018 Transplant. Proc. pmid:29731062
Levy GA Neoral is superior to FK 506 in liver transplantation. 1998 Transplant. Proc. pmid:9723293
McMaster P et al. Liver transplantation: changing goals in immunosuppression. 1998 Transplant. Proc. pmid:9723295
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Ueno T et al. Conversion to prolonged-release tacrolimus for pediatric living related donor liver transplant recipients. 2013 Transplant. Proc. pmid:23769087
Zajicek A et al. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine. 2002 Transplant. Proc. pmid:12176653
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Peltekian K et al. De novo use of low-dose tacrolimus and sirolimus in liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267318
Gómez G et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. 1999 Transplant. Proc. pmid:10500563
Khoury N et al. Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11134791
Back JH et al. Antiproteinuric Effects of Green Tea Extract on Tacrolimus-Induced Nephrotoxicity in Mice. Transplant. Proc. pmid:26293093
Baskiran A et al. Pregnancy After Liver Transplantation: Risks and Outcomes. 2017 Transplant. Proc. pmid:28923640
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Bahra M et al. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. 2002 Transplant. Proc. pmid:12431663
Miura S et al. Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. 1998 Transplant. Proc. pmid:9636492
Han SY et al. Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells. 2006 Transplant. Proc. pmid:16980053
Han SY et al. Effect of tacrolimus on the production of oxygen free radicals in hepatic mitochondria. 2006 Transplant. Proc. pmid:16980054
Montero EF et al. Gangliosides on intestinal microcirculation and animal survival during reperfusion. 2004 Transplant. Proc. pmid:15194293
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701